

Special Issue

Therapeutic Applications of Anti-Cancer Agents

Message from the Guest Editors

The newest approaches to targeted anti-cancer therapies include identifying cancer specific molecules, disrupting cellular pathways, and localizing cytotoxic agents to the tumor environment. This paradigm shift reduces the risk of toxicity and enhances efficacy. This Special Issue will focus on two broad areas: (i) bio-orthogonal chemistry based approaches, and (ii) smart biomaterial-based approaches. We welcome experts in these areas of research to share their knowledge and further the discussion on next generation anti-cancer therapeutics.

Guest Editors

Dr. Sangeetha Srinivasan

Shasqi Inc., San Francisco, United States

Dr. Jose M. Mejia Oneto

Shasqi Inc., San Francisco, United States

Prof. Dr. Glenn D. Prestwich

Washington State University, Health Sciences Spokane, Spokane, WA, USA

Deadline for manuscript submissions

closed (31 January 2019)



Bioengineering

an Open Access Journal
by MDPI

Impact Factor 3.8
CiteScore 4.0
Indexed in PubMed



mdpi.com/si/17661

Bioengineering

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
bioengineering@mdpi.com

[mdpi.com/journal/
bioengineering](https://mdpi.com/journal/bioengineering)





Bioengineering

an Open Access Journal
by MDPI

Impact Factor 3.8
CiteScore 4.0
Indexed in PubMed



[mdpi.com/journal/
bioengineering](https://mdpi.com/journal/bioengineering)



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Bioengineering* (ISSN 2306-5354). *Bioengineering* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. *Bioengineering* provides an advanced forum for the science and technology of bioengineering. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Anthony Guiseppi-Elie

Department of Biomedical Engineering, Texas A&M University, College Station, TX 77843, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPIus / SciFinder, Inspec, and other databases.

Journal Rank:

JCR - Q2 (Engineering, Biomedical) Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.6 days after submission; acceptance to publication is undertaken in 3.1 days (median values for papers published in this journal in the first half of 2024).

Recognition of Reviewers:

reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.